References
- 1. D’Angelo E, Prat J. Uterine sarcoma: a review. Gynecol Oncol. 2010; 116:131-9.10.1016/j.ygyno.2009.09.023
- 2. Wilailak S, Tansuttiwong A, Tangtrakul S. Uterine sarcomas in Ramathibodi hospital (1987-1998). Thai J Obstet Gynecol. 2000; 12:241-6.
- 3. Tavassoli FA, Davilee P, eds. World Health Organization classification of Tumours: Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.
- 4. FIGO Committee on Gynecologic Oncology. FIGO staging for uterine sarcomas. Int J Gynecol Obstet. 2009; 104:179.
- 5. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet. 2009; 105:103-4.
- 6. Sandra EB, Min Z, Timonthy C, Claudia RB. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gyneoncol Oncol. 2004; 93:204-8.
- 7. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002; 12:687-90.10.1046/j.1525-1438.2002.01151.x
- 8. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol. 2008; 134:1277-87.
- 9. Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki university central hospital 1990-2001. Gynecol Oncol. 2008; 111: 74-81.10.1016/j.ygyno.2008.06.002
- 10. Sutton G, Kavanagh J, Wolfson A, Tornos C. Corpus: mesenchymal tumors. In: Hoskin WJ, Perez CA, Young RC, Barakat RR, Markman M, Randall ME, eds. Principles and practice of gynecologic oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 873-94.
- 11. Meredith RF, Elsert DR, Kaka Z, Hodgson SE, Johnston GA, Boutselis JG. An excess of uterine sarcomas after pelvic radiation. Cancer. 1986; 58:2003-7.10.1002/1097-0142(19861101)58:9<;2003::AID-CNCR2820580908>3.0.CO;2-2
- 12. Lavie O, Barnett O, Narod SA, Rennert G. The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer. 2008; 18:352-6.10.1111/j.1525-1438.2007.01025.x
- 13. Buchanan EM, Weinstein LC, Hillson C. Endometrial Cancer. Am Fam Physician. 2009; 80:1075-80.
- 14. Sirisabya N, Manchana T, Worasethsin P, Khemapech N, Lertkhachonsuk R, Sittisomwong T, et al . Is complete surgical staging necessary in clinically early stage endometrial carcinoma? Int J Gynecol Cancer. 2009; 19: 1057-61.10.1111/IGC.0b013e3181a8ba85
- 15. Zivanovic O, Leitao MM, Iasonos A, Jacks LM, Zhou Q, Abu-Rustum NR, et al. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer staging systems. J Clin Oncol. 2009; 27:2066-72.10.1200/JCO.2008.19.8366
- 16. Raut CP, Nucci MR, Wang Q, Manolac J, Bertagnollia MM, Demetrid GD, et al. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009; 45:2818-24.10.1016/j.ejca.2009.06.030
- 17. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009; 10:1188-98.10.1016/S1470-2045(09)70226-8
- 18. Nam JH, Park JY. Update on treatment of uterine sarcoma. Curr Opin Obstet Gynecol. 2010; 22:36-42.10.1097/GCO.0b013e328334d90f
- 19. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008; 112:820-30.10.1002/cncr.23245
- 20. Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, et al. Endometrial stromal sarcoma: a population-based study. Br J Cancer. 2008; 99:1210-15.10.1038/sj.bjc.6604527
- 21. Amant F, De Knijf A, Van Calster B, Leunen1 K, Neven1 P, Berteloot P, et al. Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer. 2007; 9:1194-9.
- 22. Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Onco.l 2008; 111:82-8.10.1016/j.ygyno.2008.05.016
- 23. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as postsurgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007; 107:177-85.10.1016/j.ygyno.2007.07.070
- 24. Denschlag D, Masoud I, Stanimir G, Gilbert L. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol. 2007; 33:91-5.10.1016/j.ejso.2006.11.012